Answers are grounded in this paper and cite their sources.
In a post hoc analysis of the phase 2b study, compared with placebo, ensitrelvir demonstrated a reduced time to resolution of 5 symptoms in patients with mild-to-moderate COVID-19. Through this study, we intend to validate and establish the efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19.
No takes yet. Share an insight, caveat, or question.
Yotsuyanagi et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: